Drugs / Decellularized allogeneic human amniotic fluid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07482423 | May 2026 → May 2027 expected | androgenetic alopecia | Restore Biologics Holdings, Inc. dba Xtressé | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decellularized allogeneic human amniotic fluid | “XVIE (decellularized allogeneic human amniotic fluid) administered via intradermal scalp injection in adults with androgenetic alopecia (AGA).” NCT07482423 ↗ |
| Known as | XVIE | “This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic...” NCT07482423 ↗ |